FDA approves Lundbeck and Otsuka's Rexulti for MDD and schizophrenia

11 July 2015

The US Food and Drug Administration has approved Rexulti (brexpiprazole), from Japanese drugmaker Otsuka (TYO: 4768) and Danish CNS specialist Lundbeck (LUND: CO), as an adjunctive therapy for the treatment of adults with major depressive disorder (MDD) and as a treatment for adults with schizophrenia.

Rexulti was discovered by Otsuka and co-developed with Lundbeck. It will be co-marketed by the two companies and is expected to become available to patients in the US in early August 2015. Brexpiprazole is considered as a successor to Otsuka’s Abilify (aripiprazole), which faced patent expiration in April 2015.

Reacting to the news announced on Saturday, Otsuka’s shares gained 2.3% to 6,200.00 yen by mid-afternoon in Tokyo trading today, while Lundbeck gained 5.7% to 152.60 Danish kroner shortly after the Copenhagen market opened this morning.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK